Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Podcast | Sexual health in older age

Dr Holly Thomas helps us unpack the needlessly taboo subject of sex and sexual health in women of older age.

Listen now
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in:

18-12-2024 | Acute Kidney Injury | Research

Prophylactic trimethoprim-sulfamethoxazole is safe in adult patients with primary central nervous system lymphoma receiving high-dose methotrexate

Authors: Qinxia Xu, Ziran Li, Tianling Ding, Xiaoyan Qiu, Zhuo Wu

Published in: Annals of Hematology | Issue 1/2025

Login to get access

Abstract

This retrospective study investigated the potential drug-drug interactions between trimethoprim-sulfamethoxazole (TMP-SMZ) and high-dose methotrexate (HD-MTX) in adult patients with primary central nervous system lymphoma (PCNSL). A total of 143 Chinese adult patients with PCNSL who received 498 cycles of MTX were included. Differences in the pharmacokinetics of MTX, including Cmax, clearance (CL) and AUC0-48 h with and without co-administration of TMP-SMZ were assessed. The incidence of MTX-related acute kidney injury (AKI), hepatotoxicity, myelosuppression, and delayed MTX elimination at 48 and 72 h were also compared. Patients were divided into two cohorts for analysis: 146 cycles with TMP-SMZ exposure and 352 cycles without TMP-SMZ exposure. Patients who received TMP-SMZ concurrently with HD-MTX exhibited a 1.13-fold increase in Cmax, a 1.12-fold increase in AUC0-48 h and a reduction in CL by 0.87-fold for MTX. There was no significant difference in the incidence of MTX-related AKI, hepatotoxicity, myelosuppression, or delayed MTX elimination between the two cohorts. Prophylactic TMP-SMZ might lead to increased MTX exposure but has no impact on the incidence of myelosuppression, AKI, and hepatotoxicity. These results suggested that prophylactic TMP-SMZ is safe for adult patients with PCNSL receiving HD-MTX.
Literature
1.
Sun K et al (2022) Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma. J Clin Pharm Ther 47(12):2196–2204CrossRefPubMed
2.
Wu Z et al (2023) Germline genetic variations in methotrexate pathway are associated with pharmacokinetics, outcome, and toxicity in patients with primary central nervous system lymphoma. Expert Rev Clin Pharmacol 16(4):371–381CrossRefPubMed
3.
4.
5.
6.
Wang A et al (2022) High-dose methotrexate dosing strategy in primary central nervous system lymphoma. Leuk Lymphoma 63(6):1348–1355CrossRefPubMed
7.
Mallick S, Giridhar P (2021) Primary Central Nervous System Lymphoma, in Evidence based practice in Neuro-oncology. pp. 395–400
8.
Chukwueke U, Grommes C, Nayak L (2022) Primary Central Nervous System Lymphomas. Hematol Oncol Clin N Am 36(1):147–159CrossRef
9.
10.
May J et al (2014) High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis. Leuk Lymphoma 55(6):1345–1349CrossRefPubMed
11.
Zhou S, Aitken SL (2023) Prophylaxis Against Pneumocystis jirovecii Pneumonia in Adults. JAMA 330(2):182–183CrossRefPubMed
12.
Trubin PA, Azar MM (2023) Current Concepts in the Diagnosis and Management of Pneumocystis Pneumonia in Solid Organ Transplantation. Infect Dis Clin N Am 37(3):617–640CrossRef
13.
Weyant RB et al (2021) Pneumocystis jirovecii: a review with a focus on prevention and treatment. Expert Opin Pharmacother 22(12):1579–1592CrossRefPubMed
14.
Limper AH et al (2011) An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care Patients. Am J Respir Crit Care Med 183(1):96–128CrossRefPubMed
15.
White PL, Backx M, Barnes RA (2017) Diagnosis and management of Pneumocystis jirovecii infection. Expert Rev Anti Infect Ther 15(5):435–447CrossRefPubMed
16.
17.
Apostolopoulou A, Fishman JA (2022) The Pathogenesis and Diagnosis of Pneumocystis jiroveci Pneumonia. J Fungi, 8(11)
18.
Sohani ZN et al (2022) Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial. BMJ Open 12(7):e053039CrossRefPubMedPubMedCentral
19.
Watts CS et al (2016) Prophylactic Trimethoprim-Sulfamethoxazole Does Not Affect Pharmacokinetics or Pharmacodynamics of Methotrexate. J Pediatr Hematol Oncol 38(6):449–452CrossRefPubMedPubMedCentral
20.
Primka EJ, Camisa C (1997) Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol 36(5 Pt 2):815–818CrossRefPubMed
21.
See S, Mumford JM (2001) Trimethoprim/sulfamethoxazole-induced toxic epidermal necrolysis. Ann Pharmacother 35(6):694–697CrossRefPubMed
22.
Martins da Cunha AC, Rappersberger K, Gadner H (1991) Toxic skin reaction restricted to palms and soles after high-dose methotrexate. Pediatr Hematol Oncol 8(3):277–280CrossRefPubMed
23.
Yang CH et al (2000) Toxic epidermal necrolysis following combination of methotrexate and trimethoprim-sulfamethoxazole. Int J Dermatol 39(8):621–623CrossRefPubMed
24.
Maricic M, Davis M, Gall EP (1986) Megaloblastic pancytopenia in a patient receiving concurrent methotrexate and trimethoprim-sulfamethoxazole treatment. Arthritis Rheum 29(1):133–135CrossRefPubMed
25.
Thomas DR, Dover JS, Camp RD (1987) Pancytopenia induced by the interaction between methotrexate and trimethoprim-sulfamethoxazole. J Am Acad Dermatol 17(6):1055–1056CrossRefPubMed
26.
Levinsen M et al (2012) Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia. Eur J Haematol 88(1):78–86CrossRefPubMed
27.
Tono-oka T et al (1981) Prophylaxis of bacterial infection by sulfamethoxazole-trimethoprim (SMX-TMP) during chemotherapy in patients with childhood acute leukemia. Tohoku J Exp Med 134(3):273–279CrossRefPubMed
28.
Woods WG et al (1984) Myelosuppression associated with co-trimoxazole as a prophylactic antibiotic in the maintenance phase of childhood acute lymphocytic leukemia. J Pediatr 105(4):639–644CrossRefPubMed
29.
Ferrazzini G et al (1990) Interaction between trimethoprim-sulfamethoxazole and methotrexate in children with leukemia. J Pediatr 117(5):823–826CrossRefPubMed
30.
Beach BJ, Woods WG, Howell SB (1981) Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia. Am J Pediatr Hematol Oncol 3(2):115–119CrossRefPubMed
31.
Chan AJ, Rajakumar I (2014) High-dose methotrexate in adult oncology patients: a case-control study assessing the risk association between drug interactions and methotrexate toxicity. J Oncol Pharm Pract 20(2):93–99CrossRefPubMed
32.
Skoloda D et al (2024) Impact of Prophylactic Trimethoprim-Sulfamethoxazole on Clearance of High-Dose Methotrexate in Adult Patients. JCO Oncol Pract 20(5):673–677CrossRefPubMed
33.
Group., I.G.O.K.C.W. (2013) KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. KIDNEY INTERNATIONAL, pp 1–105
34.
Widemann BC, Adamson PC (2006) Understanding and managing methotrexate nephrotoxicity. Oncologist 11(6):694–703CrossRefPubMed
35.
Liegler DG et al (1969) The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 10(6):849–857CrossRefPubMed
36.
Evans WE, Christensen ML (1985) Drug interactions with methotrexate. J Rheumatol Suppl 12(Suppl 12):15–20PubMed
37.
Hoffman AF, Lin TL (2022) The Risks of Using Trimethoprim/Sulfamethoxazole in Patients with Renal and Cardiac Compromise. J Am Podiatr Med Assoc, 112(5)
38.
Al-Quteimat OM, Al-Badaineh MA (2013) Methotrexate and trimethoprim-sulphamethoxazole: extremely serious and life-threatening combination. J Clin Pharm Ther 38(3):203–205CrossRefPubMed
39.
Groenendal H, Rampen FH (1990) Methotrexate and trimethoprim-sulphamethoxazole–a potentially hazardous combination. Clin Exp Dermatol 15(5):358–360CrossRefPubMed
40.
Sonis ST et al (2004) Perspectives on cancer therapy-induced mucosal injury. Cancer 100(S9):1995–2025CrossRefPubMed
41.
den Hoed MAH et al (2014) Genetic and metabolic determinants of methotrexate-induced mucositis in pediatric acute lymphoblastic leukemia. Pharmacogenomics J 15(3):248–254CrossRef
42.
43.
Cudmore J et al (2014) Methotrexate and trimethoprim-sulfamethoxazole: toxicity from this combination continues to occur. Can Fam Physician 60(1):53–56PubMedPubMedCentral
Metadata
Title
Prophylactic trimethoprim-sulfamethoxazole is safe in adult patients with primary central nervous system lymphoma receiving high-dose methotrexate
Authors
Qinxia Xu
Ziran Li
Tianling Ding
Xiaoyan Qiu
Zhuo Wu
Publication date
18-12-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 1/2025
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-06146-4

Other articles of this Issue 1/2025

High resolution chest computed tomography responses for a cohort of adult with pulmonary Langerhans cell histiocytosis

The association between radiotherapy and the prognosis of follicular lymphoma patients with different characteristics in the rituximab era: a cohort study based on Surveillance, Epidemiology and End Results

Study on clinical features of early death in older patients with acute promyelocytic leukemia

Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia

Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy

Outcomes by best response with hypomethylating agent plus venetoclax in adults with previously untreated acute myeloid leukemia

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now
Video
Image Credits